Related references
Note: Only part of the references are listed.In Reply: Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era
Corey M. Gill et al.
NEUROSURGERY (2020)
The immune landscape of chondrosarcoma - potential for therapeutic targeting of CSFR1+macrophages
Iseulys Richert et al.
JOURNAL OF BONE ONCOLOGY (2020)
A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.
Peter Joseph DeMaria et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zhilin Zou et al.
CELL AND BIOSCIENCE (2020)
Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma
G. He et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report
Xiaoli Wu et al.
FRONTIERS IN ONCOLOGY (2020)
A four-factor immune risk score signature predicts the clinical outcome of patients with spinal chordoma
Ming-Xiang Zou et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor
Ming-Xiang Zou et al.
NEUROSURGERY (2019)
Clinicopathological implications of TIM3+ tumor-infiltrating lymphocytes and the miR-455-5p/Galectin-9 axis in skull base chordoma patients
Jinpeng Zhou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
The role of TNF-α in chordoma progression and inflammatory pathways
Sukru Gulluoglu et al.
CELLULAR ONCOLOGY (2019)
Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
Ruben D. Addie et al.
JOURNAL OF BONE ONCOLOGY (2019)
Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies
Ian W. Folkert et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma
Ming-Xiang Zou et al.
NEUROSURGERY (2019)
Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors
Giosue Scognamiglio et al.
BRITISH JOURNAL OF CANCER (2019)
ImmunologicCorrelates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy
Mrinal M. Gounder et al.
CLINICAL CANCER RESEARCH (2019)
Small-molecule targeting of brachyury transcription factor addiction in chordoma
Tanaz Sharifnia et al.
NATURE MEDICINE (2019)
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
Paola Magnaghi et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano et al.
LANCET ONCOLOGY (2018)
Lymphocyte-Related Inflammation and Immune-Based Scores Predict Prognosis of Chordoma Patients After Radical Resection
Wenhao Hu et al.
TRANSLATIONAL ONCOLOGY (2018)
Analysis of prognostic factors for survival in patients with primary spinal chordoma using the SEER Registry from 1973 to 2014
Yue Pan et al.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2018)
Response to PD1 inhibition in conventions chondrosarcoma
Michael J. Wagner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Clinicopathologic implications of CD8(+)/Foxp3(+) ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients
Ming-Xiang Zou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Description of the immune microenvironment of chondrosarcoma and contribution to progression
Francois A. Simard et al.
ONCOIMMUNOLOGY (2017)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients
Jianhua Zhou et al.
NEUROSURGERY (2017)
The driver landscape of sporadic chordoma
Patrick S. Tarpey et al.
NATURE COMMUNICATIONS (2017)
First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies
Denis Migliorini et al.
ONCOIMMUNOLOGY (2017)
Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
S. Stacchiotti et al.
ANNALS OF ONCOLOGY (2017)
Transcriptional Addiction in Cancer
James E. Bradner et al.
CELL (2017)
SMARCB1/INI1 Involvement in Pediatric Chordoma A Mutational and Immunohistochemical Analysis
Manila Antonelli et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology
N. Mach et al.
ANNALS OF ONCOLOGY (2016)
Skull base chordomas: clinical outcome in a consecutive series of 45 patients with long-term follow-up and evaluation of clinical and biological prognostic factors
Nicola Boari et al.
JOURNAL OF NEUROSURGERY (2016)
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype
Marie Kostine et al.
MODERN PATHOLOGY (2016)
Role of the EZH2 histone methyltransferase as a therapeutic target in cancer
Antoine Italiano
PHARMACOLOGY & THERAPEUTICS (2016)
CSPG4 as a prognostic biomarker in chordoma
Andrew J. Schoenfeld et al.
SPINE JOURNAL (2016)
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
Rika Fujii et al.
ONCOTARGET (2016)
Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis
Jiayuan Wu et al.
ONCOTARGET (2016)
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
L. Paoluzzi et al.
CLINICAL SARCOMA RESEARCH (2016)
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kimberly H. Kim et al.
NATURE MEDICINE (2015)
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
Luyuan Li et al.
PLOS ONE (2015)
Postoperative Proton Therapy for Chordomas and Chondrosarcomas of the Spine Adjuvant Versus Salvage Radiation Therapy
Emma B. Holliday et al.
SPINE (2015)
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
Johnny Suijker et al.
ONCOTARGET (2015)
Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
Yong Feng et al.
ONCOTARGET (2015)
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Christopher R. Heery et al.
CANCER IMMUNOLOGY RESEARCH (2015)
PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
Dimitrios Mathios et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Outcomes and patterns of care in adult skull base chondrosarcomas from the SEER database
Pamela S. Jones et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2014)
Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database
Pamela S. Jones et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2014)
CSF-1 Receptor Signaling in Myeloid Cells
E. Richard Stanley et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Skull Base Chordoma and Chondrosarcoma: Influence of Clinical and Demographic Factors on Prognosis: A SEER Analysis
Leif-Erik Bohman et al.
WORLD NEUROSURGERY (2014)
Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
Renee N Donahue et al.
Journal for ImmunoTherapy of Cancer (2014)
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
Duane H. Hamilton et al.
ONCOTARGET (2013)
Expression of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis
Xiaohui Liang et al.
DIAGNOSTIC PATHOLOGY (2012)
A common single-nucleotide variant in T is strongly associated with chordoma
Nischalan Pillay et al.
NATURE GENETICS (2012)
Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model
Jennifer Perez et al.
PLOS ONE (2012)
Association of Elevated HIF-2α Levels with Low Beclin 1 Expression and Poor Prognosis in Patients with Chondrosarcoma
Changbao Chen et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Increased Levels of Hypoxia-Inducible Factor-1 alpha Are Associated with Bcl-xL Expression, Tumor Apoptosis, and Clinical Outcome in Chondrosarcoma
Changbao Chen et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2011)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
M. Fernanda Amary et al.
NATURE GENETICS (2011)
Loss of SMARCB1/INI1 expression in poorly differentiated chordomas
Bret C. Mobley et al.
ACTA NEUROPATHOLOGICA (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Cranial Chondrosarcoma and Recurrence
Orin G. Bloch et al.
SKULL BASE-AN INTERDISCIPLINARY APPROACH (2010)
Hypoxia-induced downregulation of autophagy mediator Beclin 1 reduces the susceptibility of malignant intestinal epithelial cells to hypoxia-dependent apoptosis
Byong Hoon Yoo et al.
AUTOPHAGY (2009)
Chordoma and chondrosarcoma gene profile: implications for immunotherapy
Joseph H. Schwab et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
The Clinical Management of Chondrosarcoma
Richard F. Riedel et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2009)
Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes
Leida B. Rozeman et al.
MODERN PATHOLOGY (2009)
T (brachyury) gene duplication confers major susceptibility to familial chordoma
Xiaohong R. Yang et al.
NATURE GENETICS (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer
Yang Shen et al.
AUTOPHAGY (2008)
The role of hypoxia-inducible factors in tumorigenesis
E. B. Rankin et al.
CELL DEATH AND DIFFERENTIATION (2008)
Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers
Chang Hyeok Ahn et al.
APMIS (2007)
Role of autophagy in breast cancer
Vassiliki Karantza-Wadsworth et al.
AUTOPHAGY (2007)
Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas
S. Vujovic et al.
JOURNAL OF PATHOLOGY (2006)
Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation
TD Tiet et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway
E Di Carlo et al.
JOURNAL OF PATHOLOGY (2005)
T-box genes in early embryogenesis
C Showell et al.
DEVELOPMENTAL DYNAMICS (2004)
Chordoma: Natural history and results in 28 patients treated at a single institution
D Baratti et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Share Paper
